LRRC15 Protein (AA 22-538) (His tag)

Produktnummer ABIN7013689

Produktdetails

Target: LRRC15 (Leucine Rich Repeat Containing 15 (LRRC15))

Protein-Typ: Recombinant

Proteineigenschaft: AA 22-538

Spezies: Human

Quelle: HEK-293 Cells

Aufreinigungstag / Konjugat: Dieses LRRC15 Protein ist gelabelt mit His tag.

Produktmerkmale: Human LRRC15 / LIB Protein, His Tag (MALS verified)

Reinheit: >95 % as determined by SDS-PAGE.

Endotoxin-Niveau: Less than 1.0 EU per μg by the LAL method.

Anwendungsinformationen

Applikationshinweise: MALS verified

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Buffer: PBS, pH 7.4

Lagerung: -20 °C

Antigendetails

Target: LRRC15 (Leucine Rich Repeat Containing 15 (LRRC15))

Andere Bezeichnung: LRRC15 (LRRC15 Produkte)

Hintergrund: LRRC15 (Leucine-rich repeat-containing protein 15) is also known as LIB and hLib. LRRC15 is highly expressed in a variety of solid tumors. LRRC15 was expressed on stromal fibroblasts in many solid tumors (e.g., breast, head and neck, lung, pancreatic) as well as directly on a subset of cancer cells of mesenchymal origin (e.g., sarcoma, melanoma, glioblastoma). LRRC15 expression was induced by TGFβ on activated fibroblasts (αSMA+) and on mesenchymal stem cells. These collective findings suggested LRRC15 as a novel CAF and mesenchymal marker with utility as a therapeutic target for the treatment of cancers with LRRC15-positive stromal desmoplasia or cancers of mesenchymal origin. ABBV-085 is a monomethyl auristatin E (MMAE)-containing antibody-drug conjugate (ADC) directed against LRRC15, and it demonstrated robust preclinical efficacy against LRRC15 stromal-positive/cancer-negative, and LRRC15 cancer-positive models as a monotherapy, or in combination with standard-of-care therapies.

Molekulargewicht: 59.8 kDa